Evidence map›Paper›PMID 27134519›Full record

ArticleNew journal of chemistry = Nouveau journal de chimie2015

Hydrolysable core crosslinked particle for receptor-mediated pH-sensitive anticancer drug delivery.

Xifeng Liu, A Lee Miller, Brian E Waletzki, Tewodros K Mamo, Michael J Yaszemski, Lichun Lu

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in New journal of chemistry = Nouveau journal de chimie, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.3field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xifeng LiuDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA.
A Lee MillerDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA.
Brian E WaletzkiDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA.
Tewodros K MamoDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
Michael J YaszemskiDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA.
Lichun LuDepartment of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA; Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA.
Mayo Clinic · USMayo Clinic in Florida · USWinnMed · US

Funding

Metastatic Spine Tumors: Minimally Invasive Fracture Risk Analysis and Treatment - MasterR01AR056212 · NIAMS · MAYO CLINIC ROCHESTER · PI Benjamin D Elder, Lichun Lu · 2008 to 2026
$6.2M
NIAMS NIH HHS R01 AR056212
6 · The paper itself

Abstract

Biodegradable micelle systems with both extracellular stabilities and specific targeting properties are highly desirable for anti-cancer drug delivery. Here, we report a biodegradable and crosslinkable poly(propylene fumarate)-

Identifiers

PMID27134519
PMCPMC4846283
OpenAlexW1692033997

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.